Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Part of paid clinical trials in New York, New York.

Sponsor
Vitreous -Retina- Macula Consultants of New York
Study ID
NCT00403156
Phase
PHASE1
Status
Withdrawn

Conditions

  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
51 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.

Key Dates

First listed
Nov 23, 2006
Start date
Nov 30, 2006
Status verified
Dec 2015

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in combination with a daily pill of 400mg of Imatinib Mesylate in the treatment of choroidal neovascularization secondary to age-related macular degeneration

Locations (1)

FacilityCityStateZIPSite coordinators
Vitreous Retina Macula Consultants of New York, P.C.New YorkNew York10022-

Find similar trials in New York, NY

By research site
Vitreous Retina Macula Consultants of New York, P.C.· New York, NY

Related Studies